Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 16/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CD79B | P40259 | 1/20 | 0.32 |
| ▸ | CD99 | P14209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347253 | 0.87 | NT5E (0.40) | NT5EHTR2CHTR2BALDH1A1LMNA | |
| SCHEMBL20347248 | 0.84 | NT5E (0.39) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL20347249 | 0.82 | NT5E (0.36) | NT5EHTR2CHTR2BALDH1A1LMNA | |
| SCHEMBL30194829 | 0.80 | NT5E (0.48) | NT5E | |
| SCHEMBL20347283 | 0.76 | NT5E (0.44) | NT5EHTR2CHTR2BALDH1A1LMNA | |
| SCHEMBL22807217 | 0.76 | NT5E (0.44) | NT5E | |
| SCHEMBL20347251 | 0.76 | NT5E (0.44) | NT5E | |
| SCHEMBL20334131 | 0.76 | NT5E (0.53) | NT5ECD99 | |
| SCHEMBL20347252 | 0.75 | TYMP (0.42) | NT5E | |
| SCHEMBL20347254 | 0.74 | NT5E (0.53) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | disclosed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257429-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | NT5E 1/4885HTR2C 448/4885HTR2B 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.